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Abstract. Deracemisation methods have demonstrated their 
importance in the preparation of chiral compounds in the last 
years. In order to resolve a racemic mixture in a dynamic 
sense, one enantiomer of the starting material can be 
converted to the other through a deracemisation procedure, 
that can be achieved by different mechanisms based on 
stereoinversion or enantioconvergence, often involving two-
opposite half reactions, being at least one of the reactions 
enantioselective enough to finally obtain an enantioenriched 
chiral compound.  
The focus of this comprehensive review will be the 
application of deracemisation procedures in the present 
century in order to obtain optically active valuable 
compounds when employing non-metallic catalysts. Thus, 
the review will mainly focus on the use of different 
enzymatic preparations (purified enzymes, cell-free extracts 
or whole cell systems) and organocatalysts for 
deracemisation of racemic mixtures. 
1. Introduction 
2. Enzymatic deracemisation procedures 
2.1. Deracemisation by stereoinversion 
2.2. Linear deracemisation employing biocatalysts 
2.3. Cyclic deracemisations using biocatalysts 
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2.5. Other enzymatic deracemisation protocols 
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One of the most employed methodologies for the 
preparation of optically pure compounds at large 
scale includes the classical and kinetic resolution of a 
racemic mixture. Unfortunately, these methods 
present a maximum theoretical yield of 50% of the 
desired compounds, whereas the other 50% of the 
starting material is discarded.[1] In order to overcome 
this limitation, several strategies have been developed 
to transform a racemic compound into a single 
enantiomer with a 100% theoretical yield. Most of the 
described methodologies lead to the conversion of 
both enantiomers of the substrate into a single 
enantiomer of a product with high yield and optical 
purity, in a dynamic kinetic resolution (DKR) or in a 
dynamic kinetic asymmetric transformation 
(DYKAT) process.[2] However, these processes lead 
to an enantioenriched but a different chemical entity 
than the starting racemic compound, and a further 
reaction is required to obtain the enantiopure starting 
material.  
A racemic compound can be completely converted 
into a single enantiomer of the same compound 
through a deracemisation process. Deracemisation is 
a very efficient procedure to obtain optically active 
molecules, as there is no need for further steps in 
order to obtain the desired compound, thus increasing 
the atom economy of the processes. Deracemisation 
procedures consist in two half-reactions that are 
opposite in reacting direction and completely distinct 
in mechanistic pathways, provided that at least one of 
these two reactions must be enantioselective to ensure 
a successful process. Redox processes are the most 
employed approaches in order to destroy and then 
create a stereocenter in a molecule for its 
deracemisation. The catalyst or the system of 
catalysts involved in the racemization should be 
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and the reduction. Redox deracemisations have been 
mainly used for the synthesis of chiral alcohols and 
amines, as these compounds present stable oxidized 
intermediates (ketones and imines, respectively).  
Deracemisations employing different strategies have 
been widely studied, due to the intrinsic advantages 
of this type of processes.[3] Apart from those in which 
metal catalysts are involved, with a borderline 
exception,[4] we will be focusing in the last advances 
performed for the development of deracemisation 
methods using enzymes and/or organocatalysts. The 
application of both biological systems (free enzymes 
or whole cells),[5] and (relatively) small organic 
molecules, respectively, as catalysts in organic 
synthesis,[6] has gained an increasing interest in the 
recent years, being able to carry out the preparation 
of valuable compounds under mild and 
environmentally benign conditions. Both 
methodologies have been successfully combined in 
order to develop novel synthetic routes.[7] 
Deracemisation protocols have been gathered in four 
groups, according to the process taking place for the 
preparation of the chiral compound, i.e. 1) 
Deracemisation by stereoinversion (DbI); 2) Linear 
deracemisation (LD); 3) Cyclic deracemisation 
(CyD); and 4) Enantioconvergent process (EC), as 
shown in Figure 1. 
We have divided this survey in two main sections: 
enzymatic deracemisations and organocatalysed 
deracemisations. Some of the described procedures 
employed both type of catalysts. In this case, we have 




















Figure 1. Pathways involved in deracemisation procedures. 
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2 Enzymatic deracemisation 
procedures 
2.1 Deracemisation by stereoinversion 
The deracemisation by stereoinversion using different 
biocatalysts is an oxidation/reduction process in 
which one enantiomer of the racemic starting material 
is oxidized to a prochiral intermediate, which can be 
detected in small amounts in the reaction medium.[8] 
This prochiral compound is then selectively reduced 
by a catalyst with the opposite enantiopreference, 
leading to one enantiomer of the starting material 
with high yields and optical purities. Most of the 
examples of deracemisation by stereoinversion have 
been developed with secondary alcohols, compounds 
widely employed in different fields as pharmaceutical 
industry, flavour and fragrances, food and material 
sciences. Initially, some examples were successfully 
developed in presence of different ruthenium 
catalysts.[9] Regarding the use of biocatalysts, initial 
studies were developed in two-step processes. Thus, 
racemic lactate was converted into D-lactate coupling 
the L-specific oxidation of the racemate with L-lactate 
oxidase from Aerococcus viridans with the non-
selective reduction of pyruvate to racemic lactate 
with sodium borohydride.[10] Another example was 
shown in the deracemisation of racemic 2-
hydroxyacids into the (R)-enantiomers developed 
with high yields and enantioselectivities by 
combining the selective oxidation of the starting 
materials with molecular oxygen catalysed by the 
glycolate oxidase from spinach (Spinacia oleracea), 
with the non-selective reduction of the 2-oxo acids by 




























Scheme 1. Biocatalysed stereoinversion of racemic alcohols employing alcohol dehydrogenases (ADHs).[12,13]
 
In 2008 it was described the one-pot deracemisation 
of secondary alcohols using two biocatalysts in a 
tandem reaction sequence using molecular oxygen 
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(Scheme 1a).[12] Initial experiments with different 
microorganisms showed promising results when 
employing both lyophilized and resting cells of 
Alcaligenes faecalis DSM13975. Thus, enantiopure 
(S)-2-octanol (1a) was obtained from racemic 2-
octanol after 22 hours, with only a 29-41% of 2-
octanone, indicating that this excellent selectivity was 
not only due to kinetic resolution. Freshly harvested 
cells of Alcaligenes faecalis DSM13975, which 
catalyse the selective alcohol oxidation, were coupled 
with the S-selective ADH-A from Rhodococcus ruber 
DSM44541, which reduces selectively the ketone 
formed, in presence of the cofactor recycling system 
glucose dehydrogenase (GDH)/glucose. After 4 hours, 
excellent conversions and enantiomeric excesses 
were achieved for both (S)-2-octanol (1a) and (S)-
sulcatol (1b), with no presence of the respective 
ketones. This fact indicates that the reduction is the 
fastest step of the process. The use of RE-ADH 
(ADH from Rhodococcus erythropolis) or 2-propanol 
as cofactor recycling system led to the same excellent 
results. The system was extended to several 
secondary alcohols, recovering the (S)-alcohols with 
excellent yields and no trace of the ketones after 8-16 
hours. Optical purities depend on the substrate 
structure, being possible to work at substrate 
concentrations of 100 g L-1. The deracemisation was 
applied to obtain the (R)-alcohols by using an anti-
Prelog ADH as the Lactobacillus kefir (LK-ADH) in 
the reduction step. No ketone was observed for all the 
alcohols tested, being possible to achieve better 
selectivities for some substrates when compared with 
ADH-A. This methodology was carried out in a 
preparative scale starting from 485 mg of (±)-4-
phenyl-2-butanol (1c), which was treated in presence 
of Alcaligenes faecalis DSM13975, RE-ADH and 
GDH/glucose. After 16 hours at 30ºC, enantiopure 
(S)-1c was recovered in 91% yield without any other 
product in the reaction. The enzymes involved in the 
Alcaligenes faecalis DSM13975-catalysed oxidation 
of alcohols to ketones are an (R)-alcohol oxidase 
together with NADH oxidase to regenerate the 
cofactor at the expense of molecular oxygen. This 
fact allowed to develop a more general process for 
the deracemisation of racemic secondary alcohols.[13] 
Thus, a cell free extract of A. faecalis was combined 
with a NADPH-dependent (S)-selective ADH (from 
Thermoanaerobium brockii) coupled with formate 
dehydrogenase (FDH)/formate for cofactor recycling. 
At these conditions, racemic 1a was completely 
converted to the (S)-enantiomer with 48% ee after 16 
hours. It was observed that two cofactor-recycling 
systems could be employed in solution with different 
purposes. One system was used to recycle the oxidize 
NAD+, whereas the other one to reduce NADPH. In 
view of this, a novel system with purified ADHs was 
developed, as shown in Scheme 1b. The oxidation 
step was catalysed by the (R)-selective LK-ADH, 
selecting the FMN-dependent YcnD from Bacillus 
subtilis as NADPH oxidase to regenerate this cofactor. 
For the reduction, the NADH-dependent (S)-selective 
ADH-A was employed together with a NADH-
specific FDH. At these conditions, a wide variety of 
racemic alcohols were converted into their (S)-
enantiomer with complete enantioselectivity and 
yield in times ranging from 6 to 24 hours. The ADHs 
can be exchanged by related biocatalysts with a 
different enantiopreference in order to obtain the (R)-
alcohols. Thus, when the NADPH-dependent (S)-
selective ADH from Thermoanaerobium brockii was 
combined with the NADH-dependent (R)-selective 
ADH-PR2 in presence of YcnD and FDH for the 
cofactor regeneration, the corresponding (R)-alcohols 
were achieved with high yields and optical purities. 
The deracemisation of 1-phenylethanol (1f) was 
performed at 50 mg scale using LK-ADH and ADH-
A. After 16 hours at 30ºC, enantiopure (S)-1f was 
recovered in 90% isolated yield. 
Resting cells of Candida albicans were able to 
catalyse the deracemisation of 1-phenylethanol (1f) 
by combining the oxidative kinetic resolution of the 
racemic alcohol to acetophenone (2f), with the 
bioreduction of 2f catalysed by different anti-Prelog 
alcohol dehydrogenases.[14] Lactobacillus brevis CCT 
3745 (LBADH) was shown to be the best catalyst, as 
(R)-1f was achieved from acetophenone with 90% 
yield and 99% ee after 24 hours. When C. albicans 
cells immobilized onto calcium alginate beads were 
used in the oxidation of racemic 1f in presence of 
acetone to regenerate the NAD+ cofactor, and after 
this, free L. brevis cells were added with 2-propanol 
to regenerate the NADH required for the reductive 
step, enantiopure (R)-1f was obtained with complete 
conversion after 17 hours. In a similar fashion, the 
deracemisation using L. brevis cells for the oxidation 
step and C. albicans cells for the reduction one was 
also studied to yield (S)-alcohol, but with lower ee 
than for the (R)-enantiomer. The use of the 
immobilized cells during the first step of the process 
simplify the work-up of the reactions, as these cells 
can be removed from the medium before the 
reduction step and reused in further four oxidative 
steps.  
In 2016 it was described the one-pot deracemisation 
of racemic 1-phenyl-1,2-ethanediol to its (R)-
enantiomer by employing a de novo multi-enzymatic 
system.[15] After testing more than 20 oxidoreductases, 
it was found than the ketoreductase from Candida 
parapsilosis CCTCC M203011 (SCR1) was the best 
biocatalyst in the enantioselective bioxidation of (S)-
1-phenyl-1,2-ethanodiol to 2-hydroxyacetophenone 
in presence of NADP+. This ketone was selectively 
reduced by KRD from Zygosaccharomyces rouxii 
ATCC14462 using NADPH as cofactor, in order to 
obtain (R)-1-phenyl-1,2-ethanediol with high optical 
purity. Optimization of reaction parameters as 
temperature, pH, biocatalysts ratio and 
NADP+/NADPH, afforded the (R)-alcohol with 91% 
yield and 99% ee after 8 hours when combining both 
enzymes. Reactions were carried out at 30ºC in 
aqueous buffer pH 7.0 with an activity ratio of 
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Stereoinversions have been also applied to carry out 
the deracemisation of racemic amines, by combining 
two ω-transaminases (ω-TAs) for the synthesis of 
these optically pure compounds.[16] In 2009, the 
deracemisation of racemic primary amines in a one-
pot two-step process was described, combining the 
kinetic resolution of the starting amine with a 
reductive amination step of the formed ketone 
(Scheme 2).[17] The kinetic resolution of the racemic 
amines was tested in presence of different 
transaminases with pyruvate as amine acceptor. Three 
commercial enzymes (ATA-113, ATA-114 and 
ATA-117) were selected, achieving the enantiopure 
amines after 24 hours with conversions close to 50%. 
ATA-1134 and ATA-114 led to the (S)-amines, 
whereas ATA-117 afforded the (R)-amine. This 
kinetic resolution was coupled with the selective 
amination of the ketone formed in the first step 
employing a second ω-transaminase (with opposite 
enantiopreference to the first one) and L-alanine as 
amine donor. In order to shift the ketone-amine 
equilibrium, the pyruvate formed in this step was 
removed using lactate dehydrogenase (LDH) in a 
coupled reaction system. The optical purity of the 
amines formed was moderate, due to a partial 
catalysis of the amination step by the first ω-
transaminase. To overcome this issue, after 
completion of the kinetic resolution, the reaction was 
heated up to 75ºC for 30 minutes to inactivate the 
first biocatalyst and then the second biocatalyst was 
added. Despite the enzyme lost using this method, 
enantiopure (R)- or (S)-amines were obtained with 
high conversions, depending on the addition order of 
the enzymes. The reaction was scaled up to 50 mg 
(20 mM concentration) for the deracemisation of 1-
cyclohexylethan-1-amine (3a). After 48 hours, the 
enantiopure (S)-3a was obtained with 98% 
conversion (92% isolated yield). When starting from 
racemic 1-(2,6-dimethylphenoxy)-2-propanamine 
(3b), enantiopure (S)-3b was recovered with 95% 
yield. In a further development to avoid the need of 
inactivate the ω-TA employed in the kinetic 
resolution, two opposite enantioselective ω-TAs were 
used in the one-pot one-step deracemisation of 
racemic primary amines.[18] In the first step, the (S)-
enantiomer of the amine was converted to the ketone 
by a (S)-ω-TA in presence of an amino acceptor. In 
the second step, the ketone is converted to the (R)-
amine using a (R)-selective ω-TA and an amino 
donor. As a requisite, the (R)-ω-TA has to show a 
very low activity toward the amino acceptor used in 
the first step. For this process, the (R)-selective ω-
TAs from Mycobacterium vanbaalenii (ω-TAMV) 
and from Neosartorya fischeri (ω-TANF) and the (S)-
selective from Polaromonas sp. JS666 (ω-TAPO) and 
Vibrio fluvialis JS17 (ω-TAVF), were studied. The 
specificity of these enzymes on different amine 
acceptors (seven ketoacids and two ketoesters) was 
tested, being observed that the use of 2-
oxopentanedioic acid was the best choice, as it is 
inexpensive and showed a high activity for the 
Polaromonas sp. JS666 transaminase and no activity 
for the (R)-selective biocatalysts. In addition, the side 
product glutamate can be easily removed from the 
reaction. After separately optimization of the two 
reaction steps, namely the kinetic resolution and the 
amination; deracemisation of α-methylbenzylamine 
(3f, 50 mM) was performed in presence of pyridoxal 
phosphate (PLP) as cofactor and LDH for removing 
2-oxopentanedioic acid. After 48 hours, enantiopure 
(R)-methyl benzyl amine was recovered with almost 
complete conversion when using both ω-TAPO/ω-
TAMV and ω-TAPO/ω-TANF. This system was 
extended to the deracemisation of other aromatic 
amines, obtaining the enantiopure (R)-enantiomers 
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By the same year, a similar method was carried out 
for the effective deracemisation of mexiletine (3b, 
Scheme 3),[19] a chiral amine clinically used in 
cardiac disorders, currently employed as racemate. 
Besides, the (S)-enantiomer has attracted attention 
due to the potential use in neuromuscular 
disorders.[20] Authors developed a one-pot two-steps 
procedure featuring a kinetic resolution followed by a 
stereoselective amination. This strategy lies on the 
sequential activity of two enantiocomplementary -
transaminases, thus leading to any 3b enantiomer 
(depending on the addition order of the -
transaminases) with the concomitant recycling of the 
cosubstrate (pyruvate) needed by the action of an 
amino acid oxidase (AAO). Thus, in the first step a 
(R)-selective -transaminase was applied to 
selectively transform the (R)-enantiomer into the 
corresponding ketone using pyruvate/D-AAO 
catalytic system in the presence of O2. In a second 
step, a (S)-selective -transaminase catalysed the 
formal reductive amination of the formed ketone into 
enantiopure (S)-mexiletine using ammonium cation 
released in the previous step and L-alanine in 
catalytic amounts (see Scheme 3a). This L-alanine 
was recycled from pyruvate using an L-alanine 
dehydrogenase (AADH). In a similar fashion, the use 
of a (S)-selective -transaminase in the first step 
together with a (R)-selective one for the reductive 
amination of the ketone led to enantiopure (R)-3b, as 
shown in Scheme 3b. On a bigger scale, this 
procedure was successfully applied to the preparation 
of 100 mg of each enantiomer of mexiletine in 48 h 
working at 28 mM substrate concentration. 
A further development for the application of two 
enantiocomplementary -transaminases in the 
synthesis of optically amines has been recently 
published by applying an engineered metabolic 
pathway.[21] Thus, the deracemisation of several 
aromatic and aliphatic racemic amines to the (S)-
enantiomers has been carried out by combining the 
deamination catalysed by the (R)-selective ω-TA 
from Arthrobacter sp. (ARTA) in presence of 
pyruvate as cofactor, with the deamination of the 
ketones formed catalysed by the (S)-selective ω-TA 
from Ochrobactrum anthropi (OATA), using 
isopropylamine as amine source, as shown in Scheme 
4. Due to the fact that pyruvate and isopropylamine 
are substrates for both ARTA and OATA, a number 
of secondary undesired reactions can occur during the 
deracemisation process. These secondary reactions 
have been suppressed by carrying out process and 
protein engineering strategies, controlling the 
reaction pathway to achieve only the desired 
reactions. The combination of thermodynamic and 
kinetic control afforded the (S)-amines with excellent 
results both in vivo and in vitro. The processes have 
been improved by using an ARTA mutant with 
improved activity, whereas the metabolic removal of 
acetone form the reaction medium supresses some 
undesired side reactions. Both ω-TAs have been 
expressed in E. coli cells where native glycolysis or 
reinforced deamination of L-threonine has been 
exploited to supply α-keto acid to the system. As an 
example, (S)-α-methylbenzylamine can be achieved 























Scheme 3. Deracemisation of mexiletine (3b) employing -transaminases.[19]
In a different approach, the combination of 
engineered amine oxidases (AOs) and imine 
reductases (IREDs)[22] in a one-pot reaction, allowed 
the deracemisation by stereoinversion of cyclic 
amines, affording enantioenriched 2-substituted 
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(Scheme 5). In this approach, starting from the 
racemic amine, either the (S)-selective monoamine 
oxidase from Aspergillus niger (MAO-N)[23] or the 
(R)-selective 6-hydroxy-D-nicotine oxidase 
(E350L/E352D variant)[24] from Arthrobacter 
nicotinovorans (6-HDNO),[25] selectively oxidizes 
one enantiomer of amine 4 to the imine 5, whereas 
the antipode remains intact. Then, the IRED 
stereoselectively reduces the formed imine into the 
amine but of opposite handedness. In this way, half of 
the starting material remains untouched while the 
other half undergoes stereoinversion. In order to 
obtain the highest enzymatic activity for both 6-
HDNO/MAO-N and IRED enzymes, different 
reaction conditions were screened, such as pH, buffer 
concentration and cosubstrate (glucose). It must be 
emphasized that the selectivity of both MAO and 
IRED should match and has to be carefully checked 
for each substrate. With the optimized conditions, the 
one-pot system was scaled up. Thus, (S)-2-
phenylpiperidine was produced on a 0.25 g scale 
starting from the racemic amine. Finally, a substantial 
improvement in terms of atom economy and a time 
reduction of 2-4 h in the deracemisation process was 
observed using IRED (DbI) instead of ammonia 























Scheme 5. Stereoinversion of 2-substituted pyrrolidines and piperidines by combining monoamine oxidases and imine 
reductases.[25]
 
In 2019 it has been described the deracemisation of a 
set of racemic amines to the corresponding (R)- or 
(S)-enantiomers by combining ω-TAs and amine 
dehydrogenases(AmDHs) in a biocatalytic cascade 
process.[26] In order to obtain the (R)-amines, the 
initial step consist in the selective deamination of 
racemic amines catalysed by different (S)-selective 
ω-TAs, as shown in Scheme 6. Best results were 
achieved by whole-cells of the ω-TA from 
Polaromonas sp. JS666 (ω-TAPO). The second step 
was the (R)-selective amination of the ketones 
obtained, catalysed by L-phenylalanine 
dehydrogenase of Rhodococcus sp. (Rs-AmDH) or a 
chimeric AmDH (Chi-AmDH). Processes were 
optimized at pH 9.5 employing formate 
dehydrogenase (FDH) from Pseudomonas sp. and 
glucose dehydrogenase (GDH) from Bacillus subtilis 
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the ω-TA whole-cell processes optimized, they were 
tested in tandem for the deracemisation of different 
racemic aromatic and aliphatic amines. After 
optimizing the use of 15% v/v of DMSO as cosolvent 
and modifying the vector system for the expression of 
the AmDHs, high conversions were obtained for 
almost all the amines tested (80-99%) with excellent 
enantioselectivities (ee>99%).  
The same approach was further employed for the 
preparation of the enantiopure (S)-amines. Thus, the 
enantioselective deamination of racemic amines was 
catalysed by (R)-selective AmDHs, followed by the 
enantioselective amination by (S)-selective ω-TAs. 
Unfortunately, the equilibrium of both processes was 
highly unfavourable. In order to obtain synthetically 
valuable reactions, benzylamine was employed as 
amino donor as in the ω-TA-catalysed aminations. 
Benzaldehyde formed in the deamination of 
benzyalmine is used by the aldehyde reductase 
(AHR) from Synechocystis sp. to give benzyl alcohol 
and regenerate NAD+ cofactor for AmDH. The 
efficiency of this system when coupling AmDH with 
the ω-TA from Vibrio fluvialis JS17 was tested in the 
deracemisation of 4-phenylbutan-2-amine to its (S)-
enantiomer with complete conversion and 95% ee 
after 24 hours in presence of 20 mM benzylamine and 
0.2 mM benzaldehyde. A set of 13 racemic amines 
was tested, achieving the corresponding (S)-amines 












Scheme 6. Deracemisation of racemic amines to the (R)-enantiomers combining ω-TAs and amine 
dehydrogenases(AmDHs).[26] 
2.2 Linear deracemisation employing biocatalysts 
Linear deracemisations are slightly different to the 
stereoinversion protocols, as in this case, both 
enantiomers of the starting material are oxidized to a 
prochiral intermediate, which is selectively reduced 
to a single enantiomer of the starting material with 
high yields.  
This methodology has been also applied to the 
preparation of chiral secondary alcohols. Thus, the 
deracemisation of 2,2’-dichloro-1-phenylethanol (6) 
was performed through linear deracemisation 
employing an iridium catalyst for the oxidation of the 
alcohol to the ketone, and an ADH for the selective 
bioreduction of the ketone in a one-pot process.[27] 
But this deracemisation occurred with a moderate 
selectivity, being recovered (R)-6 with 40% ee. In 
order to improve this result, a novel methodology was 
described in 2014. Thus, the one-pot alcohol 6 
oxidation catalysed by the Trametes versicolor 
laccase /TEMPO system, was followed by the 
selective reduction of ketone 7 employing E. coli 
ADH-A cells (Scheme 7).[28] After 24 hours of the 
laccase/TEMPO oxidation at pH 4.5 in presence of 
tert-butyl methyl ether (MTBE) at 33% v/v as 
cosolvent, pH was adjusted to 7.5 by addition of Tris 
and HCl, in order to inactivate the laccase. Then E. 
coli ADH-A and iso-propanol as hydrogen donor 
(10% v/v) was added. After 48 hours at 30ºC, (R)-6 
was recovered with complete conversion and 97% ee. 
An interesting example in which two different 
enzymes are used in the oxidation/reduction process 
has been shown in the linear deracemisation of 
profenol (2-phenyl-1-propanol, 8), the key core of 
NSAID drugs.[29] A laccase/TEMPO system was 
employed for the oxidation of the alcohol to form a 
racemic aldehyde which is then selectively reduced 
by ADHs through a dynamic kinetic resolution 
(DKR) process (Scheme 8). The Trametes versicolor 
laccase/TEMPO system was able to catalyse the 
oxidation of the starting alcohol at 30 mM 
concentration with 85% conversion after 2 hours. A 
15% of the overoxidation product (carboxylic acid) 
was observed, so the substrate concentration was 
increased to 90 mM to reduce this byproduct. ADH 
from E. coli (ADH-P) and Horse Liver ADH 
(HLADH) were used for the bioreduction to obtain 
the (S)-alcohol whereas evo-1.1.200 was employed 
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studied starting from the racemic alcohol. After the 
laccase catalysed oxidation, the bioreduction was 
carried out without isolation of the aldehyde. For all 
the ADHs, high conversions (>95%) and good 
enantioselectivities (86-87% ee) were obtained. The 
deracemisation was also performed in a one-pot 
process at 150 mg of starting material. The 
laccase/TEMPO catalysed oxidation of the alcohol 
during 3.5 hours in citrate buffer pH 5.5 led to the 
aldehyde. Then, the reaction was diluted with 
phosphate buffer adjusting the pH to 8.0 for HLADH 
and 9.0 for evo.1.1.200 in order to inactivate the 
laccase. Then NADH and iso-propanol (IPA, 5% v/v) 
were added, obtaining the (S)- or (R)-enantiomer of 
the product depending on the chosen ADH, with 
yields around 70% and optical purities of 82-86%. 
Given that stereocenters at the alpha position of an 
aldehyde carbonyl are readily epimerized through 
tautomerisation, a DKR process took place. The 
decrease in the optical purity of the product observed 
in comparison with the single bioreduction reaction 




















Scheme 8. Deracemisation of profenol (8) combining a non-stereoselective oxidation process followed by an 
enantioselective bioreduction under dynamic conditions.[28] 
In the last few years, some sequential deracemisation 
examples of racemic alcohols have been described 
including an initial step of non-selective 
organocatalytic oxidation of the starting alcohol to a 
prochiral ketone, followed by an enantioselective 
reduction step catalysed by different enzymes. This 
strategy was followed for the preparation of chiral 
primary and secondary alcohols, in which the 
oxidation process was performed by using 
organocatalysts such as TEMPO or AZADO (2-
azaadamantane N-oxyl) and the bioreduction was 
carried out in presence of alcohol dehydrogenases. 
Thus, a set of aromatic and aliphatic secondary 
racemic alcohols were converted into the pure 
enantiomers in one-pot procedure, in which the 
nonselective oxidation using TEMPO/iodine was 
followed by the bioreduction of the prochiral ketone 
formed using ADH with different selectivities.[30] 
After studying different oxidants, it was observed that 
best results for the alcohol oxidation in aqueous 
buffer were obtained TEMPO/iodine system, as this 
catalyst allowed the system to work in one-pot, since 
the activity of the ADH remained unaltered. 
Nevertheless, an inorganic reductant (Na2S2O3) was 
required to quench the excess of iodine used in the 
first step, prior to the bioreduction. The optimum 
conditions for the complete oxidation of 1-
phenylethanol into acetophenone were found in 
buffer Tris/HCl pH 10.0 using 0.2 equivalents of 
TEMPO and 1.5 equivalents of iodine at 30ºC after 
sonication of the mixture for 1 hour. This method 
could be extended to other aromatic and aliphatic 
racemic alcohols. For most of the substrates tested, 
complete conversions were achieved after 1 hour. 
The oxidation system was combined with the 
bioreduction catalysed by the Prelog E.coli/ADH-A, 
without the need of an external cofactor. Enantiopure 
(S)-alcohols were recovered after 24 hours with 
conversions higher than 95% for a set of aromatic and 
aliphatic substrates. When the anti-Prelog NADH-
dependent ADHs as LBADH or evo-1.1.200 were 
employed, the (R)-alcohols (>99% ee) could be 
produced from racemates with conversions over 90%. 
A similar approach has been recently developed in 
the one-pot deracemisation of a wide variety of 
racemic aliphatic and aromatic sec-alcohols (Scheme 
9). In this procedure, AZADO was employed as 
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NaOCl in combination with different alcohol 
dehydrogenases.[31] Commercial ADHs from 
Codexis© were able to selectively reduce all the 
ketones tested to the (S)- or (R)-enantiopure alcohols 
with complete conversions in presence of IPA as 
cosubstrate in a substrate coupled approach for the 
regeneration of the nicotinamide cofactor. AZADO, 
combined with NaOCl, shows a high catalytic 
potential and can be employed in the oxidation of 
hindered secondary alcohols. In order to effectively 
coupling the AZADO-catalysed oxidation with the 
bioreduction employing the ADHs, the main 
parameter to control was the salt concentration 
reached after the oxidation (NaCl from the NaOCl 
and carbonate species form the NaHCO3 used to 
lower the pH from the commercial NaOCl solution). 
At the standard conditions, this concentration was 
very high, which reduces the solubility of the 
resulting ketone and leads to an incomplete reduction. 
To overcome this issue, addition of NaHCO3 in the 
first step was suppressed controlling the pH of the 1-
(4-trifluoromethyl)-phenylpropan-2-ol oxidation (250 
mM) with phosphate buffer. After 1.5 hours of 
AZADO/NaOCl catalysed oxidation, IPA, NADP+, 
the ADH and phosphate buffer pH 7.0 were added to 
reach a 100 mM alcohol concentration, leading to a 
complete conversion of (S)-alcohol after 24 hours. 
This method was extended to other alcohols, being 
observed that for some of them, conversions were not 
complete. A further dilution process in the reduction 
step was necessary, in order to work at ketone 










Scheme 9. Deracemisation of secondary alcohols in one-pot by the non-selective oxidation reaction with AZADO 
organocatalyst and the enantioselective reduction by alcohol dehydrogenases.[31] 
2.3 Cyclic deracemisations using biocatalysts  
A process in which a selective biocatalysed process 
in one redox direction is combined with a non-
selective reaction in the opposite direction that, after 
a certain number of redox cycles, furnish an optically 
enriched product starting from its racemate is often 
called cyclic deracemisation (CyD). The idea behind 
this system is that the non-reactive enantiomer 
accumulates during the process whereas the reactive 
one is converted into the achiral intermediate, 
provided that one biocatalyst is enantioselective 
enough. The most common approach makes use of 
selective oxidative enzyme along with a non-selective 
reductant. In this way, several sec-alcohols and 
amines have been deracemised through the 
corresponding achiral keto- or imino- (iminium-) 
derivative, respectively. Although far less explored, 
the joint use of a selective reductive enzyme and a 
non-selective oxidant can be set up, as the example 
show below for the deracemisation of sulfoxides. 
Chiral sulfoxides can be also obtained through redox 
deracemisation procedures.[32] Methionine sulfoxide 
reductase A (MsrA) was employed, as this biocatalyst 
is excellent for the synthesis of chiral sulfoxides by 
kinetic resolution, reducing selectively one of the 
enantiomers of the starting sulfoxide to the sulfide 
(Scheme 10).[33] This enzyme accepts a wide range of 
aromatic methyl and ethyl sulfoxides. In order to 
carry out effective kinetic resolutions in presence of 
E. coli cells expressing MsrA, a 5% v/v of an organic 
cosolvent as n-decane was required as reservoir of the 
formed sulfides. The development of this biphasic 
system allowed looking for a lipophilic oxidant able 
to oxidize the sulfide back to the racemic sulfoxide 
and returning to the catalytic cycle in a cyclic 
deracemisation process. Oxidant optimization showed 
that the easy-to-synthesize oxaziridine I was the best 
choice for performing the deracemisation, as it was 
compatible with the E. coli cells and showed a good 
reactivity. Thus, racemic p-bromophenyl methyl 
sulfoxide (10a) was treated with the E. coli cells 
overexpressing MsrA in buffer containing the oxidant 
and 5% v/v n-decane. After 24 hours, a 79% yield of 
(R)-10a was isolated with >99% ee. In view of these 
results, different sulfoxides were deracemised, 
recovering the enantiopure (R)-enantiomers with 
yields from moderate to high (52-90%). This 
procedure was also applied to the deracemisation of 
the anti-inflammatory drug sulindac. Due to its low 
water solubility, 1.0 equivalent of β-cyclodextrin was 
added. After 24 hours, a 61% of (R)-sulindac with 
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Scheme 10. Cyclic deracemisation for the preparation of 
optically active sulfoxides.[32] 
Resting cells of Candida albicans CCT 076 are able 
to selectively oxidize (S)-1-phenylethanol (1f) to 
acetophenone (2f), which was then reduced by a 
partially (S)-selective enzyme.[14] In this way, (R)-1f 
was accumulating after several redox cycles in a 
cyclic deracemisation, in which the oxidation step 
was highly selective and fast, whereas the reduction 
was slower and partially selective. After 6 days, 
chiral alcohol can be obtained with 82% isolated 
yield and 98% ee. 
In a pioneering work, an extremely selective 
monoamino oxidase variant, MAO-N, was obtained 
through directed evolution by using a wild type MAO 
isolated from Aspergillus niger as starting point. 
After ca.150000 colonies screening, the authors were 
able to find and characterize this improved mutant 
(Asn336Ser), not only in terms of activity but also in 
terms of enantioselectivity (from 17:1 to >100:1 
towards rac-α-methyl benzylamine 3f) With this 
biocatalyst in hand, a CyD process was envisaged as 
shown in Scheme 9 and therefore, a set of readily 
available reductants were screened (NaBH4, Pd/C-
HCOONa, NH3·BH3) being amine borane complex 
best suited for this CyD process.[34] Thus, the whole 
system was challenged towards rac-α-methyl 
benzylamine (1 mM) and (R)-3f was isolated in 77% 





















Scheme 11. CyD of racemic secondary amines employing amine oxidase and a chemical reductant.[35] 
2005, an improvement of the previously reported 
amine CyD was achieved by random mutagenesis and 
screening over the MAO isolated from Aspergillus 
niger.[35] In this report, the authors were able to 
identify and characterise a MAO-N variant that 
readily accepted and efficiently deracemised 
secondary amines when combined with a typical non 
selective reducing agent NH3·BH3. Firstly, E. coli 
whole cells overexpressing the double mutant MAO-
N Asn336Ser/Ile246Met was used in analytical scale 
to screen possible substrates with different structural 
features. With the best accepted substrates, 
preparative scale CyD reactions where performed at 
20 mM substrate concentration (Scheme 11a). The 
enzyme was purified and covalently immobilised 
onto Eupergit C resin, affording a robust catalyst that 
facilitated purification and improved isolated yields, 
albeit at a lower rate. Best results were obtained in 
the deracemization of racemic 1-
methyltetrahydroisoquinoline (11) at 20 mM 
concentration, furnishing the (R)-enantiomer with 
99% ee, 95% isolated yield in 96 h (the whole cells 
afforded 71% isolated yield and 99% ee in 48 h). 
Besides, higher scale deracemization (14.7 g/L) at 
100 mM was successfully applied to 2-
phenylpyrrolidine, thus leading to (R)-enantiomer, 
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Scheme 12. CyD of racemic primary amines employing 
amine oxidases and a chemical reductant.[36] 
In 2012 (Scheme 12) a related work was reported 
dealing with either whole cell biocatalyst (E. coli 
overexpressing cyclohexylamine oxidase CHAO 
derived from Brevibacterium oxydans IH-35A) or 
crude enzymatic preparation instead of fungal or 
mammalian-derived enzymes.[36] Employing such 
bacterial biocatalysts together with ammonia-borane 
complex for the efficient CyD of rac--methyl 













Scheme 13. Cyclic deracemisation of amino esters by employing cyclohexylamine oxidase and NH3·BH3.[37] 
A recent application of these CHAO enzymes has 
been shown in the CyD of amino esters (14a-b). A set 
of mutations was performed in the entrance of the 
active site to widen the substrate acceptance.[37] In 
this line, the CHAO mutants were able to resolve rac-
valine and rac-phenylalanine as ethyl esters 
derivatives, among other amino acids. By combining 
E. coli/CHAO mutant (Y321I/M226T) and NH3·BH3 
at pH 6.5 and 30 °C, an efficient CyD was 
accomplished. After acid hydrolysis, a 95% yield was 
obtained for D-valine (14a, Scheme 13a). 
Interestingly, for rac-phenylalanine ethyl ester (14b, 
Scheme 13b), a complete reversal of 
enantioselectivity was observed as compared with the 
wild type CHAO, thus affording the unexpected L-
14b. Crispine A (16) is an alkaloid isolated from 
Carduus crispus, for which there are several 
enantioselective syntheses reported. In particular, a 
CyD approach was developed employing MAO-N5 
variant and amine-borane complex, affording 16 in 
overall 48% yield and >97% ee after 40 hours of 















Scheme 14. Cyclic deracemisation of crispine A (16) 
employing MAO-N5 and its mutant.[38]  
The authors noticed that a similar compound lacking 
the two methoxy groups in the aromatic ring, 
afforded a similar result after only 6 hours. Thus, in a 
further publication, a rational redesign of the MAO-
N5 was conducted in order to fix the steric limitations 
exerted by these two methoxy groups. To do so, 
mutant libraries replacing key amino acids were 
constructed and screened. The more active mutant 
was selected for further rounds of optimization. In 
this way, a 990-fold increase in the specific activity 
was achieved for MAO-N-9C, a mutant featuring 
four mutated residues (F210L, L213T, M242Q and 
M246T9) from MAO-N5. This mutant allowed the 
deracemisation of crispine A in only two hours.[39] 
In the field of natural product asymmetric synthesis, 
Turner´s group developed a CyD strategy for the 
asymmetric synthesis of a series of tetrahydro-β-
carbolines (THBCs, 18). This kind of heterocyclic 
compounds, with complex molecular architectures, is 
an important family of bioactive alkaloids and 
constituted a source of inspiration for many synthetic 
organic chemists. In this work, the authors carried out 
the successful CyD of 1-substituted β-carbolines 
derivatives employing MAO-N variants (Scheme 
15).[40] 
In this way, using a variant of MAO-N in 
combination with NH3·BH3 as a non-selective 
chemical reducing agent, the deracemisation of these 
compounds was accomplished thus achieving the -
carboline derivatives with high optical purity in most 
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different variants of the monoamine oxidase from 
Aspergillus niger (MAO-N) were evaluated. 
Furthermore, an influence of the C1-substituent of the 
β-carbolines derivatives was observed. Thus, by 
increasing the size and lipophilicity of this substituent, 
an increase in the optical purity of the deracemised 
product was observed. For both enzyme variants, a 
switch in enantiopreference was observed, regarding 
to the nature of this substituent. For bulkier substrates, 
the MAO-N variants exhibit (R)-selectivity. The 
factors that influence this enantioselectivity were 
explored by docking simulation of both MAO-N 
variants examining the different binding modes of the 
substrates. As expected, these studies showed that the 
steric issues exerted by C1 substituent into the active 
site, is a key factor that influences the selectivity 


















Scheme 15: CyD of 1-substituted β-carbolines derivatives using the MAO-N/ NH3·BH3 system.[40]  
More recently, this protocol was expanded to other 
challenging cyclic amines such as 2-substituted 
piperidines, morpholines, thiomorpholines and 
piperazines. Two enanticomplementary MAO 
enzymes were successfully applied for the CyD of 
these substrates, id est, MAO-N variants and 6-
hydroxy-D-nicotine oxidase E350L/E352D. Thus, by 
using this CyD protocol, both enantiomers were 
easily accessible in up to 99% ee and high 
conversion.[41] 
Recently, in the quest for biocatalysts with broader 
substrate spectrum, Zhu, Lau and co-workers 
engineered cyclohexylamine oxidase (CHAO) and 
applied it in the deracemisation of secondary amines. 
Taking into account that CHAO has the advantage 
high substrate specificity on alicyclic amines and sec-
alkylamines; rounds of saturation mutagenesis in 
active sites residues were performed. The activity of 
CHAO variants was evaluated in the deracemisation 
of 2-substituted tetrahydroquinolines (THQs, 20), 
valuable alkaloids with a broad spectrum of 
biological activities. In this way, comparative studies 
of enzymatic activity between wild type CHAO (wt 
CHAO) and mutant CHAOs were carried out. The 
results suggest a much higher activity of the mutant 
CHAOs towards secondary amines than wt CHAO, 
which prefers primary amines.[42] Furthermore, steric 
factors are responsible of a reduced enzyme activity 
of the mutant CHAOs toward 2-subtituted THQs, 
observing higher conversion for methyl group over 
allyl>benzyl>phenyl substitution. On the other hand, 
the mutant CHAOs resulted more selective for the 
(S)-enantiomers. Finally, a preparative scale for the 
deracemisation of 2-methyl-THQ with mutant CHAO 
in combination with NH3·BH3 was performed, 
affording the corresponding (R)-2-methyl-THQ after 
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Scheme 16: Deracemisation of 2-substituted-tetrahydroquinolines (THQs, 18) using CHAO variants.[42] 
As an extension of the CyD, Zhu, Wu, Lau and co-
workers developed a new library of CHAO mutants 
in order to evaluate the deracemisation process 
towards a family of 2-subtitued-THQs.[43] For all the 
substrates evaluated, high ee values and isolated 
yields were obtained (>91% and >57%, respectively). 
Furthermore, the protein engineering of CHAO based 
on the modification of a series of amino acid residues 
located in the vicinity of the active site of the enzyme, 
allowed access, in some cases, to the 
enantiocomplementary 2-subtitued-THQs. 
Specifically, for 2-isopropyl and 2-cyclopropyl-THQ 
the (S)-enantiomer was preferred for one of the 
CHAO mutants. To explain this observation, 
molecular dynamics (MD) were carried out, 
evaluating representative structures of the substrate 
coordinating to N-atom of FAD. In all the cases, a 
correct distance (< 2.5 Å) between the N-atom of 
FAD and the H-atom of the stereogenic carbon for 
the (S)-enantiomer, was observed. Theoretical studies 
together with engineering enzymatic work provide a 


















Scheme 17. Synthesis of 2-substituted-THQs through Rh-catalysed formal [4+2] cycloaddition followed by CyD 
employing amine oxidases.[46] 
By the same time, Marsden, Turner, and co-workers 
developed a sequential process for the asymmetric 
synthesis of 2-substituted THQs), previously isolated 
from Galipea officinalis, with antimalarial activity.[44] 
Such an approach consists in the efficient application 
of a chemo- and biocatalytic sequential process. 
Using the same strategy previously reported by 
Marsden,[45] the nitrogen heterocycles could be 
obtained through a rhodium-catalysed formal [4+2] 
cycloaddition of ortho-aminophenylboronic acids 
with Michael acceptors. This methodology was 
extended to the synthesis of THQ natural products 
obtaining moderate to good isolated yields.[46] In 
order to complete the asymmetric synthesis of THQ, 
deracemisation process was carried out, evaluating 
tree different AOx enzyme variants (MAO-N D9, 
CHAO and 6-HDNO) (Scheme 17). For all the 
substrates, CHAO showed good activity, giving 
optical purities of 47-99%. Only 2-pentenyl-THQ, 
was substrate of all tested enzymes, being a suitable 
substrate for the MAO-N D9 with an 85% ee after 96 
h. Finally, preparative scale was examined, 
demonstrating the potential application of these rather 
deracemisation process in combination with 
chemocatalysis for the efficient preparation of 
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Scheme 18. CyD of primary and secondary amines using the AspRedAm/NH3·BH3 system.[47]
Recently, an elegant approach was reported by 
Turner and co-workers, which involves the use of 
NADP(H)-dependent reductive aminase 
(AspRedAm) from Aspergillus oryzae in an oxidative 
way, in replacement of MAO-N system. In this case, 
in order to recycling the NADP+ co-factor, the 
combination with a NADPH oxidase (NOX) was 
employed. Finally, applying a non selective chemical 
reducing agent (NH3.BH3), a complete 
deracemization can be attained. After 24h of reaction, 
a series of amines can be obtained with high 
conversion (74-98 %) and selectivity (93-99% ee) of 
the desired enantiomer by using 
enantiocomplementary biocatalysts (Scheme 18). 
Additionally, the employed AspRedAm variant 
allowed access to novel amine products, which are 
not substrate of the MAO-N variants, thus showing 
the complementarity this alternative system.[47] 
It is clear that the strategic combination of different 
catalytic processes, has gained attention for the 
synthetic community and, nowadays, interesting 
applications can be found in the literature. In this 
context, the recent work reported by Wenger, Ward 
and co-workers explores the possibility of merging 
photoredox and biocatalysis toward the asymmetric 
synthesis of amines.[48] Visible-light photoredox 
catalysis has emerged as an attractive methodology to  
generate radical intermediates in mild and controlled 
conditions. Besides, biocatalysis brings about high 
selectivity and efficiency in a simple way. With this 
in mind, the authors proposed a cyclic amine 
deracemisation by the joint action of a monoamine 
oxidase (MAO-N-9), which catalyses the selective 
oxidation of one of the enantiomers to the 
corresponding amine, followed by the generation of 
-amino alkyl radicals via photo-reduction of the 
corresponding cyclic imine and subsequent hydrogen 
atom transfer (HAT) process. Under these conditions, 
enantioenriched amines can be successfully obtained 
by a CyD process (Scheme 19). In order to allow both 
catalytic processes to run concurrently, a novel water-
soluble trisulfonated variant of fac-[Ir(ppy)3] 
photocatalyst was prepared. Additionally, ascorbic 
acid (AscH2/AscH-) was used to drive the HAT 
process. Kinetic studies revealed that the biocatalytic 
oxidation is the rate determining step in the overall 
reaction system. Finally, photobiocatalysis was 
evaluated for 2-subtistituted cyclic amine, attaining 
high yields and high ee (>95% and >98 %, 
respectively) for the butyl or cyclohexyl groups. 
However, for benzyl substituent, the process failed in 
the biocatalytic step, obtaining only 8% of the 
corresponding (R)-isomer. Likewise, when 1-methyl-
3,4-dihydroisoquinoline was evaluated, a racemic 
product was obtained. This observation could be 
explained by the higher stabilization of the -amino 
radical, leading to a less exergonic HAT pathway. 
For these cases, the use of a more polar hydrogen 
donor may accelerate the HAT process, obtaining a 
35% ee for 1-methyl-3,4-dihydroisoquinoline when 
4-mercaptophenylacetic acid or 3-mercaptopropionic 
acid derivatives, were used. Although the exploration 
of others cyclic amines was limited, this work 
demonstrates the fruitful cooperation between 
photocatalysis and biocatalysis, opening the 
possibility of novel processes design to get access to 
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Scheme 19: Combining photoredox and biocatalysis toward the asymmetric synthesis of amines in a CyD procedure.[48] 
A very elegant approach for cyclic amines 
deracemisation has been recently achieved by 
successfully encompassing the action of evolved S-
selective MAO-N from Aspergillus. niger and 
artificial metalloenzymes (Scheme 20), in this case 
the so-called ‘artificial transfer hydrogenase’ 
(ATHase).[49] Thus, the use of borane-based reductant 
has been replaced by a catalytic system based on an Ir 
complex attached to biotin in order to ensure the 
binding to streptavidin (or its mutants) in a rather 
specific and favourable fashion. Remarkably, since 
the Ir complex is buried into the streptavidin scaffold, 
the biocatalysts are protected from mutual 
inactivation. Another aspect to be highlighted is the 
need of consuming as soon as formed the H2O2 
(released as by-product of the MAO-N) which 
inactivates the ATHase. To get rid of this oxidant, 
catalase was efficiently incorporated into the system. 
In this way, two structurally different compounds, -
methyl tetrahydroisoquinoline (22) and 2-cyclohexyl 
pyrrolidine (23) were successfully deracemised (99 % 
conversion and >99 % ee for the R-enantiomer in 
both cases) employing these three enzyme concurrent 
process that consumes O2 and formate as oxidant and 
hydrogen-donor, respectively. Protein engineering 
played a crucial role in this work, since both MAO-N 
and streptavidin (Sav) mutants were screened and 
combined in order to maximise the final 
enantioselectivity. Authors pointed out that the 
stereochemical outcome of the overall system is 
governed by the MAO-N. Considering that the 
ATHase stereoselectivity is not perfect, the process is 
















Scheme 20. Cyclic deracemisation of racemic secondary amines 22-23 employing MAO-N and artificial ATHase.[49]
2.4 Enantioconvergent processes 
A less explored strategy for the efficient 
deracemisation of valuable chiral compounds are the 
so-called enantioconvergent processes, in which both 
enantiomers of the starting substrate undergo 
different reaction pathways that finally converge into 
the same enantiomer (or homochiral pair of similarly 
reactive compounds). In a broad sense, 
enantioconvergent processes can be regarded as 
deracemisation by stereoinversion, since one 
enantiomer will keep the original stereochemistry 
while the antipode will undergo inversion in its 
handedness. However, the DbI can be distinguished 
from EC because in former there is a destruction-
recreation sequence in the stereochemical information 
[for instance (S)-sp3-sp2-(R)-sp3] whereas in EC 
processes the stereoinversion takes place by SN2 
mechanism, as in epoxide hydrolase- or sulfatase-
catalysed deracemizations.[50] Similar processes have 
been deeply studied in the hydrolysis of racemic 
epoxides by using jointly both retaining- and 
inverting-epoxide hydrolases, sulfatases and 
dehalogenases.[51] 
Apart from the biocatalysed deracemisation strategies 
using redox enzymes, some other examples have 
been described employing hydrolases. Some of these 
hydrolase-catalysed deracemisations include the 
selective enzymatic hydrolysis of an ester followed 
by a Mitsunobu inversion reaction onto the formed 
alcohol. Overall, this strategy comprising kinetic 
resolution and Mitsunobu inversion, can be 
considered an ER. Thus, in 2009 it was performed the 
effective preparation of optically active 1,2-diol 
monotosylate O-acetyl-derivatives (24) using 
different lipases and polymer-bound 
triphenylphosphine for the Mitsunobu reaction 
(Scheme 21).[52] Lipase PS was able to selectively 
hydrolyse a set of 2-acetoxy tosylates in phosphate 
buffer pH 6.5 at 30ºC containing 10% of diiso-propyl 
ether (DIPE), leading to the (R)-alcohols and (S)-
esters with an excellent enantioselectivities (E>100). 
For the Mitsunobu inversion reaction, the use of a 
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DEAD and acetic acid facilitated the product 
separation by filtration and allowed for smoothly 
reaction, recovering the (S)-enantiomer of the ester 
from the (R)-alcohol in 1 hour with complete 
conversion and 99% ee. The sequential 
deracemisation combining the two steps led to the 
final 2-acetoxy-1-tosylated diols with excellent 
optical purities (93-98% ee) and high yields (73-91%), 
depending on the substrate structure. Such a protocol 
was succesfully applied for the preparation of 
valuable heterocyclic compounds such as alkaloids 




















Scheme 21. Deracemisation of 1,2-diol monotosylates derivatives (24) by the combination of selective lipase-mediated 
hydrolysis and the Mitsunobu inversion.[52] 
The same procedure was employed by Bouzemi and 
co.[54] in the deracemisation of a set of 
arylalkylcarbinol derivatives (26) employing the 
lipase B from Candida antarctica (CalB) and the 
Mitsunobu inversion. CalB was able to catalyse the 
selective hydrolysis of the racemic starting material 
to the (R)-alcohols and (S)-acetates with high 
selectivity.[55] Lipase amount is a key parameter in the 
enantioselectivity of the kinetic resolution. Thus, 
decreasing the amount of lipase improves both 
reactivity and selectivity. After CalB removal by 
filtration, the crude mixture of unreacted (S)-26 and 
(R)-27 were treated with triphenylphosphine (PPh3), 
diisopropylazadicarboxylate (DIAD) and acetic acid 
at 0 °C to convert the formed (R)-alcohols into the 
corresponding (S)-acetates. Both the inversion 
selectivity and the yield depended on the substrate 
aromatic substituents. CalB presented (R) 
enantiopreference, so the (R)-acetates were 
hydrolysed by the enzyme and converted into (S)-
acetates by Mitsunobu inversion in a biphasic system 
(Scheme 22). The (S)-acetates were obtained in 71%–











Scheme 22. Deracemisation of arylalkylcarbinols using CalB and Mitsunobu inversion.[54]
2.5. Other enzymatic deracemisation protocols 
A different deracemisation pathway using hydrolytic 
reactions was developed in the synthesis of non-
natural L-2-aryl-amino acids (28) by a 
chemoenzymatic route using a highly active and 
stereoselective recombinant penicillin G acylase 
(PGA).[56] The N-phenylacetyl derivatives (29), were 
selectively hydrolysed by the PGA to the L-
enantiomer, whereas the unreacted D-enantiomer 
could be racemised by heating for recycling in a 
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this procedure was the biocatalyst screening in order 
to find a PGA with high stereoselectivity and activity 
towards the racemic substrates. The overexpressed 
recombinant PGA from the fermentation broth of B. 
subtilis WB800/pPZW103-PGA, was able to 
selectively hydrolysed N-phenylacetyl derivatives of 
the 2-arylamino acids with excellent 
enantioselectivity (E>200) and conversions close to 
50% after short reaction times. The position and type 
of the substrate substituents influenced the PGA 
activity but selectivity was not affected.  
When the hydrolysis catalysed by the recombinant 
PGA of 28a (X: o-Cl) was carried out at 
multimilligram scale, a conversion close to 50% was 
achieved after 4 hours in a process with excellent 
selectivity and a catalyst productivity (grams of 
product per gram of catalyst) of 58.7 g/g. After the 
enzymatic hydrolysis, the supernatant was acidified 
with HCl in order to precipitate the unreacted D-29a 
and phenylacetic acid. The pH of the aqueous 
solution was adjusted to 7.0 to recover L-28a. The 
mixture of the recovered D-enantiomer and 
phenylacetic acid was heated at 170 °C for 15 min 
and then cooled. After this treatment, the D-
compounds were completely racemised and 
employed as substrates in a new reaction cycle, being 



















Scheme 23. Synthesis of enantiopure non-natural L-2-arylamino acids by chemoenzymatic deracemisation using PGA.[56] 
3. Organocatalysed deracemisations 
Even when there are fewer examples than by using 
biocatalysts, some deracemisation protocols using 
organocatalysts have been developed in the last 
years.[6] Most of these examples have been performed 
using redox catalysts, whereas others are based in 
acid/base catalysis to ensure a proper deracemisation 
of the starting materials..  
In 2013 it was described the CyD of different 3H-
indolines (30) through their oxidation to the 
corresponding 3H-indoles using an oxopiperidinium 
salt (Bobbitt’s salt) in toluene under anionic phase-
transfer conditions, and the selective reduction of the 
3H-indoles generated by employing a Hantzsch ester 
in presence of a chiral phosphoric acid catalyst,[57] as 
shown in Scheme 24.[58] The process was carried out 
in a biphasic system, in which the substrate is 
dissolved in organic solvent, the oxidant and the 
reductant are solids and water can be also present in 
the reaction media. As the selectivity of the oxidation 
step is very low, the high selectivity of the reduction 
step allows the effective deracemisation, as observed 
for linear deracemisation methodologies. The 
reaction optimization showed that the best conditions 
were found by using as solvent a mixture n-
hexane/Et2O/water in proportion 9:1:10, using 1.0 
equivalent of hydrochloric acid as additive in 
presence of 1.5 equiv. of oxopiperidinium II, the 
Hantzsch ester IIIa (1.55 equiv.) and 10 mol% of the 
chiral phosphoric acid (S)-TRIP (IVa). 3H-Indolines 
presenting several substitution pattern were tested to 
this deracemisation procedure. 2-Aryl substituted 
substrates led to the (S)-30 with good yields and high 
optical purities. Similar conditions were employed for 
the deracemisation of substituted 
tetrahydroquinolines in order to obtain the (R)-
enantiomers with high yields and enantiomeric 
excesses, being required 3.0 or more equivalents of 
oxidant and reductant due to a second oxidation from 
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Scheme 24. Deracemisation of racemic 3H-indolines 
employing organocatalysts.[58]
 
The redox deracemisation of cyclic ethers could 
occur through an oxocarbenium intermediate that 
then has to be selectively reduced.[59] In order to 
overcome the stability issues of the oxocarbenium 
intermediates, the addition of protic additives able to 
react with them, is required. This additive makes the 
conversion of the racemic ether 31 into the acetal 32, 
which in presence of a chiral Brønsted acid catalyst 
would lead to the chiral ion pair 33, and then 
asymmetric hydrogen transfer through chiral anion 
catalysis would afford the desired (R)-31. Thus, 
initial experiments were performed in the 
deracemisation of 6H-benzo[c]chromene (31a, 
Scheme 25a), a motif occurring in the structure of 
different valuable compounds.[60] Hantzsch ester IIIa 
and a chiral phosphoric acid were employed in the 
asymmetric hydrogenation. Different oxidants were 
tested in absence of additive, but very poor (if any) 
enantioselectivities were achieved, being required 
higher amounts of oxidant. The addition of protic 
additives led to complete oxidation even with 1.05 
equivalents of oxidant, obtaining (R)-chromene with 
the highest enantioselectivity in presence of DDQ and 
methanol with molecular sieves. The best phosphoric 
acid for this process was IVb, whereas the solvent 
optimization afforded the chiral compound in 93% 
yield and 93% ee in a mixture of MTBE and DCM. 
Mechanistic studies confirm that an acetal 
intermediate is involved in the deracemisation 
process and that the presence in this acetal of a 
methoxy group as leaving group has a positive effect 
in terms of a selective asymmetric transfer 
hydrogenation. By this reason, methanol was selected 
among other additives.   
These optimized conditions were then extended to 
other 6H-benzo[c]chromenes. For most of the 
compounds tested, a substituent in the arene ring led 
to good results, achieving the (R)-compounds with 
good yields and optical purities up to 99%. 
Chromenes presenting aryl and heteroaryl groups at 
the α-position also led to the optically active 
substrates with high selectivities. Reactions can also 
be performed with starting materials containing α-
alkyl, -allyl, -alkenyl and -alkynyl groups with 
excellent yields and high optical purities. This linear 
deracemisation protocol was also tested in the 
deracemisation of isochromans with high yields and 
optical purities. For these substrates, Na2CO3 was 
required as additive instead of MeOH, in order to 
avoid undesired reactions that occur between the 
reaction intermediate and some DDQ species 
generated in the medium. Using Na2CO3 (0.5 equiv.), 
the chiral isochroman was recovered with 90% ee. 
Different substituted 1H-isochromenes were tested, 
being observed that all the α-aryl and α-alkyl 
derivatives were deracemised under the standard 
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Scheme 25. a) Organocatalysed deracemisation of 6H-benzo[c]chromene, b) Deracemisation of 1,3,4,9-
tetrahydropyrano[3,4-b]indoles using DDQ and a chiral phosphoric acid.[60,62]
Chiral 1,3,4,9-tetrahydropyrano[3,4-b]indoles (34, 
THPIs) are valuable structures present in many 
biologically active compounds, but there are very few 
examples of their enantioselective synthesis.[61] In 
2018 the redox deracemisation of a set of α-
substituted THPIs was proposed employing DDQ as 
oxidant and a chiral phosphoric acid for the 
asymmetric hydrogenation through chiral anion 
catalysis (Scheme 25b).[62] Compound 34a was 
selected as model substrate, being observed that the 
presence of a protic additive led to a completion in 
the oxidation step, and the highest selectivity was 
achieved in presence of a stoichiometric amount of 
EtOH. Process optimization led to the SPINOL-chiral 
phosphoric derivative IVc as the best catalysts in 
presence of a DCM/Et2O mixture at 0ºC containing 
4.0 Å molecular sieves. Once obtained the best 
conditions for the CyD, a set of α-aryl substituted 
THPIs were subjected to the deracemisation, being 
recovered (S)-34 with high yields and enantiomeric 
excesses (80-96% ee), with no effect of the electronic 
properties of the aryl group at α-position. 1-Naphthyl, 
2-furyl and 2-thienyl groups were also successfully 
deracemised. The use of indoles with different groups 
in the aromatic ring also led to the enantioenriched 
starting material with yields higher than 90% and 
excellent optical purities, whereas no reaction was 
observed for the α-methyl derivative. The positive 
effect of EtOH as additive was studied, being 
established that in the presence of DDQ and EtOH a 
ketal intermediate was formed in the deracemisation, 
which in presence of the chiral phosphoric acid 
afforded the contact ion pair formed by the 
oxocarbenium and the chiral phosphate. The last step 
is the selective reduction of the tight ion pair by 
Hantzsch ester IIIb.  
Apart from the redox approach to perform 
organocatalysed deracemisation, some other 
methodologies have been developed. Thus, in 2012, 
List et al. achieved the effective deracemisation of α-
aryl hydrocoumarins (35), compounds with 
biologically active properties, by using a three-step 
procedure that comprises the dithioketal protection of 
the starting material, the asymmetric Brønsted acid-
catalysed cyclization of the ketene dithioketal to the 
corresponding ortho ester and the final hydrolysis to 
obtain the enantiopure α-substituted lactone.[63] The 
asymmetric catalytic cyclization of the ketene 36 was 
carried out in cyclohexane at room temperature in 
presence of different chiral phosphoric acids. The use 
of the commercially available compound IVd at 10 
mol% led to a 95% conversion and an 80% ee after 2 
hours. Catalyst loading can be reduced even to 0.5%, 
being achieved a 93% yield after 2.5 days and 87% ee. 
Good results could be also obtained with IVe at 5 
mol%, with an excellent selectivity (90% ee), but a 
lower activity (99% after 1 week). The use of IVd,e 
(5 mol%) was extended to other ketene dithioketals 
with high yields and enantioselectivities regardless 
the electronic nature of the ketene. Once optimized 
this process, the deracemisation of 1.9 g of 
hydrocoumarin 35a was performed, as shown in 
Scheme 26. First, this compound was converted in 
the achiral ketene dithioketal 36a with 1,3-
propanedithiolate and trimethylaluminum, and 
isolated by precipitation in diethyl ether. The 
dithioketal was dissolved in cyclohexane at room 
temperature in presence of 0.5 mol% of catalyst IVd 
to yield 37a, which was treated after 48 hours with 
I2/NaHCO3 to obtain enantiopure (S)-35a with 
quantitative yield. According to the Figure 1, this 
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Scheme 26. Organocatalysed deracemisation of α-aryl hydrocomoumarins in a three-step procedure.[63] 
Optically active sulfones are present in a wide range 
of biologically active compounds, being developed 
several methodologies for their synthesis.[64] A 
method to obtain these compounds consist in 
performing an enantioselective -elimination reaction 
in order to generate an olefinic product, whereas the 
unreactive enantiomer of the racemic sulfone is 
recovered.[65] This kinetic resolution was successfully 
performed by treating 0.1 mmol/mL of starting 
sulfone with a chiral BINOL-derived polyether (10 
mol%) containing a 3,3`-diiodo-substitution pattern 
in the aromatic ring, using 1,4-dioxane as solvent and 
1.5 equivalents of KF as base. These conditions were 
extended to several (hetero)aryl sulfones with good 
results. In order to overcome the limitation of the 
kinetic resolutions, the formed α,β-unsaturated ketone 
was converted into the starting β-sulfonyl ketones 
using sulfinic acid. Thus, after the first kinetic 
resolution, the enone was quantitavely converted in 
racemic starting material and then another kinetic 
resolution was carried out. After three of these cycles, 
chiral (R)-sulfonyl ketone was achieved with 85% 
yield and 97% ee. Overall, this procedure can be 
regarded as an organocatalised CyD. 
4. Other metal-free deracemisations 
Despite the extensive use of biocatalysts for the 
deracemisation of compounds in absence of metals 
along with the organocatalysed processes, there are 
other few procedures in which metal free 
deracemisations are accomplished.  
The host-guest inclusion complexation technique, 
which has been usually employed in the kinetic 
resolution of racemates,[66] has been successfully 
applied for the deracemisation of α-substituted cyclic 
ketones under basic conditions. This approach can be 
also used in the deracemisation of α-hydroxyketones 
(Scheme 27).[67] Thus, racemic 2-benzyloxy-3-
pentanone was tested as substrate in the base-
catalysed racemization combined with the 
asymmetric inclusion complexation in order to obtain 
the chiral starting material. The racemization of the 
starting material worked well with different inorganic 
bases, being selected K2CO3 due its mild basicity. As 
chiral host, the (-)-TADDOL derivative V was 
employed in stoichiometric amounts. When the 
reaction was performed in a mixture MeOH/H2O 1:1 
at room temperature, the chiral ketone was obtained 
with 97% and 49% ee after three days, whereas the 
chiral host was recovered quantitatively. The increase 
in the substrate concentration allowed obtaining a 
much higher optical purity of ketone (S)-1, achieving 
this compound with 96% ee. This methodology was 
extended to other acyclic α-hydroxy ketones, being 
necessary to modify the substrate concentration and 
the base in order to optimize the results for each 
substrate. In general, excellent yields and moderate to 

















Scheme 27. Deracemisation of α-hydroxyketones by host-guest inclusion complexation.[67]  
The Viedma Ripening is a method that allows the 
conversion of a racemic mixture of a solid substance 
into a single enantiomer with a theoretically 100% 
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suspension of racemic conglomerate crystals in 
combination with racemization in solution, thus 
resulting in the complete deracemisation in the solid 
phase. There are some requirements in order to 
perform the Viedma Ripening: First, the target 
molecule must undergo racemization in solution, and 
second, the enantiomers of the molecule must 
crystallize as separate crystals, forming a racemic 
conglomerate. Most of the examples in which 
compounds have been deracemised by this technique 
include amino acids and derivatives, as well as 
organometallic compounds.[69] In 2017, the 
deracemisation of several allylic sulfoxides was 
studied, as these compounds are able to racemise at 
temperatures close to 50ºC.[70] From all the sulfoxides 
tested, only allyl 4-nitrophenylsulfoxide was able to 
crystallize as a racemic conglomerate, so it was 
employed for the Viedma ripening experiments. This 
compound racemised at room temperature in toluene 
and diethyl ether. Using toluene at room temperature 
led to a 12% ee of the sulfoxide after one month, and 
this result was employed for further optimization. 
Thus, employing refluxing diethyl ether as solvent, 
and creating an initial bias, a complete 
deracemisation of the compound was observed after 8 
days.  
5. Conclusions and Future Perspectives 
In the last ten years, a huge number of deracemisation 
protocols have been developed in order to obtain a 
chiral compound starting from its racemic mixture. 
Most of the examples have been described using 
biocatalysts, whereas the use of organocatalysts for 
this purpose is still in its infancy. Excellent results 
can be achieved specially in the preparation of chiral 
alcohols and amines using stereoinversion or cyclic 
deracemisation through redox processes, involving 
the formation of an oxidized compound and the 
following reduction to the chiral starting material. 
Once optimized, these methodologies present the 
advantage that there is no need of further reactions in 
order to obtain the target molecules, something 
required in other approaches as the dynamic 
resolutions, whereas the theoretical yields can be up 
to 100%, impossible in the classical kinetic 
resolutions.  
By these reasons, deracemisation processes have 
become an attractive alternative to the traditional 
strategies such as kinetic resolution and dynamic 
processes. The enormous variety of (bio)catalysts that 
(bio)chemists have been lately developing, with 
broader substrate acceptance profile, raised 
thermostability and robustness, increases the 
possibilities of novel deracemisation designs with the 
combination of selective and efficient catalysts in 
harmonic fashion. It seems obvious that the state-of-
the-art technologies such as continuous flow systems, 
photochemistry, preparative electrochemistry and 
mechanochemistry, to name just a few, will be more 
integrated to complex deracemisation systems, 
thereby providing a better use of resources and a 
remarkable improvement of the overall process 
sustainability. 
Although the biocatalysis and organocatalysis has 
reached a high level of sophistication, not only novel 
reactions but also known reactions running through a 
novel mechanism are reported in the literature every 
day.[71] It seems obvious in this line and owing to 
their intrinsic advantages, deracemisation protocol 
designs shall involve such ever-growing source of 
elements to develop efficient systems. Thus, 
deracemisation will become a sustainable alternative 
to traditional methodologies currently employed to 
obtain highly demanded enantioenriched compounds. 
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